Skip to Main Content

Polimanti Chosen to Receive One Mind Rising Star Computational Psychiatry Research Award

August 24, 2021

Renato Polimanti, PhD, MSc, Assistant Professor of Psychiatry, has been chosen to receive the One Mind Rising Star Computational Psychiatry Research Award.

Polimanti will present his research at the Scientific Symposium portion of the 27th Music Festival for Brain Health at Staglin Family Vineyard in Rutherford, Calif., on September 11, 2021.

The One Mind Rising Star Research Awards are a vital catalyst to accelerate neuropsychiatric science by identifying and funding the most promising emerging leaders whose pivotal, innovative research aims to improve lives worldwide. Each awardee receives a $300,000 grant over three years to fund their studies plus opportunities for leadership development, networking and, where appropriate, scaled implementation of their discoveries.

The complexity of internalizing disorders such as post-traumatic stress, depression, and anxiety limits the translation of genetic risk factors into predictive tools doctors can use to identify and treat at-risk individuals. Polimanti will develop novel analytic strategies based on integration of different perspectives including disease-specific modeling, the integration of genetic information with other molecular data, and the assessment of the interaction with environmental risk factors

By developing reliable instruments, Polimanti’s work can help healthcare professionals implement preventive strategies and early intervention to help people thrive.

The 2021 One Mind Rising Star Award winners were selected with the assistance and recommendations of the One Mind Scientific Advisory Board, which includes 10 of the leading brain scientists in the world, noted for their pioneering research in their respective fields.

One Mind is a leading mental health non-profit that heals lives through brain research, working from science to services to society. It launched the Rising Star Awards in 2005 under the fundamental principle that cutting edge, high-risk research would enable breakthroughs to accelerate cures for the neuropsychiatric illnesses that affect 1 in 4 people worldwide.